More

    Bharat Biotech starts human trial for COVAXIN

    Must Read

    Health ministry: No case of post-vaccination hospitalisation reported so far

    India kicked off the largest COVID-19 immunisation drive in the world, with over a lakh vaccinations today....

    PM Modi to flag off eight trains connecting different regions of country to Statue of Unity in Kevadiya this morning

    Prime Minister Narendra Modi will flag off eight trains connecting different regions of the country to Kevadiya...

    17 january – Know your today’s horoscope

    Aries:Your biggest asset is your sense of humour try to use it to cure your illness. Businessmen...

    The human trial of Bharat Biotech’s anti-COVID-19 vaccine Covaxin began at Rohtak’s Post-Graduate Institute of Medical Sciences on Friday, Haryana Health Minister Anil Vij said.

    The minister also said the vaccine has been administered to three persons who have shown no adverse effect to it.

    Doctors at the Rohtak PGIMS, meanwhile, told reporters that three volunteers were administered the vaccine as part of the first phase of the clinical trial.

    They said the process might take six months, but over the next two-three months, the effect of the vaccine would be assessed from the antibodies generated and any adverse reaction caused, if any.

    The volunteers are in the age group of 30 to 40 years.

    The vaccine will now be administered to ten persons who like the three would be observed on a regular basis.

    In the second phase, more vaccine candidates will be enrolled and the vaccine dosage would also be increased, they said.

    Bharat Biotech got the country’s drug regulator’s approval to start clinical trials of its anti-Corona vaccine Covaxin recently.

    There are over seven anti-corona vaccines at various stages of development in the country with two of them having received the drug regulator’s go-ahead to start the human clinical trials of their vaccines.

    Earlier on Wednesday, drug firm Zydus had said it has started human clinical trials of its COVID-19 vaccine candidate ZyCoV-D. In this phase of trials, the company will be enrolling over 1,000 subjects across multiple clinical study sites in India, it had said in a regulatory filing.

    Zydus had got the approval a few days after India’s first indigenous COVID-19 vaccine candidate COVAXIN, developed by Bharat Biotech in collaboration with Indian Council of Medical Research and National Institute of Virology, got the nod for human clinical trials from the Drug Controller General of India.

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here

    This site uses Akismet to reduce spam. Learn how your comment data is processed.

    Latest News

    Health ministry: No case of post-vaccination hospitalisation reported so far

    India kicked off the largest COVID-19 immunisation drive in the world, with over a lakh vaccinations today....

    PM Modi to flag off eight trains connecting different regions of country to Statue of Unity in Kevadiya this morning

    Prime Minister Narendra Modi will flag off eight trains connecting different regions of the country to Kevadiya today through video conferencing. These...

    17 january – Know your today’s horoscope

    Aries:Your biggest asset is your sense of humour try to use it to cure your illness. Businessmen today may incur losses in...

    Approximately 79 percent vaccination at 4 centers of Vadodara district on the first day

    On the first day of covid vaccination, approximately 79% of the beneficiaries in rural areas of Vadodara district have been vaccinated.  

    Covid 19 cases reached 22533 in Vadodara after 74 new cases on Saturday

    Total 65 discharged from hospital taking the total to 21212 The number of positive cases in Vadodara reached 22533...

    More Articles Like This

    - Advertisement -